Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Escape maps are consistent with viral mutations selected in cell culture and a persistently infected patient. (A) Viral escape mutations selected by Regeneron with spike-pseudotyped VSV in cell culture in the presence of antibody (12). (B) Escape maps like those in Fig. 1A, but showing only mutations accessible by single-nucleotide changes to the Wuhan-Hu-1 sequence, with nongray colors indicating mutations in cell culture (red), the infected patient (blue), or both (purple). Figure S5 shows these maps colored by how mutations affect ACE2 affinity or RBD expression. (C) Dynamics of RBD mutations in a patient treated with REGN-COV2 at day 145 of infection (black dot-dash vertical line). E484A rose in frequency in linkage with F486I, but because E484A is not an escape mutation in our maps, it is not shown in other panels. See also fig. S4. (D) The escape mutations that arise in cell culture and the infected patient are single-nucleotide–accessible and escape antibody binding without imposing a large cost on ACE2 affinity [as measured using yeast display (7)]. Each point is a mutation, with shape and color indicating whether it is accessible and selected during viral growth. Points farther to the right on the x axis indicate stronger escape from antibody binding; points higher up on the y axis indicate higher ACE2 affinity.](https://figures.cochat.ai/paper-figures/91cf075ab18741e0a80bfb01ad2b708a/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-2.jpg)

![Fig. 4 Structural context of escape mutations. (A) Escape maps projected on antibody-bound RBD structures. [REGN10933 and REGN10987: Protein Data Bank (PDB) ID 6XDG (11); LY-CoV016: PDB ID 7C01 (13)]. Antibody heavy- and light-chain variable domains are shown as blue cartoons, and the RBD surface is colored to indicate how strongly mutations at that site mediate escape (white indicates no escape, red indicates strongest escape site for that antibody or cocktail). Sites where no mutations are functionally tolerated are colored gray. (B) For each antibody, sites were classified as direct antibody contacts (non-hydrogen atoms within 4 Å of antibody), antibody-proximal (4 to 8 Å), or antibody-distal (>8 Å). Each point indicates a site, classified as escape (red) or non-escape (black). The dashed gray line indicates the cutoff used to classify sites as escape or non-escape (see materials and methods for details). Red and black numbers indicate how many sites in each category are escape or non-escape sites, respectively. Interactive visualizations are at https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/, and hypothesized mechanisms of escape and additional structural details for labeled points are shown in fig. S6.](https://figures.cochat.ai/paper-figures/854cbba408614d74b93381682c26dd9e/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, 61–70).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD, which increases the affinity for the ACE2 receptor (57, 58), and a D614G mutation, which increases virion spike density, infectivity, and transmissibility (59, 60).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Snakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 2
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Regeneron Pharmaceuticals Inc. “Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization ” press release (21 November 2020); https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive/.
Cited by
Items 401–500 of 750
Zhao, F., Keating, C., Ozorowski, G., Shaabani, N., Francino-Urdaniz, I. M., Barman, S., Limbo, O., Burns, A., Zhou, P.-P., Ricciardi, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104914 · Cited by 14
Targeting Viral Surface Proteins through Structure-Based Design
Narkhede, Y. B., Gonzalez, K. J., & Strauch, E. (2021) · Viruses · doi:10.3390/v13071320 · Cited by 16
Ronapreve for prophylaxis and treatment of covid-19
Sidebottom, D. B., & Gill, D. (2021) · BMJ · doi:10.1136/bmj.n2136 · Cited by 14
Focosi, D., Maggi, F., McConnell, S. A., & Casadevall, A. (2022) · Future Microbiology · doi:10.2217/fmb-2021-0286 · Cited by 13
David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors
Alfaleh, M. A., Zawawi, A., Alamri, S. S., & Hashem, A. M. (2022) · mAbs · doi:10.1080/19420862.2022.2057832 · Cited by 13
Barnes, J. E., Lund-Andersen, P. K., Patel, J. S., & Ytreberg, F. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-23482-5 · Cited by 15
Enhancing global preparedness during an ongoing pandemic from partial and noisy data
Klamser, P., d’Andrea, V., Lauro, F. D., Zachariae, A., Bontorin, S., Nardo, A. D., Hall, M. D., Maier, B. F., Ferretti, L., Brockmann, D., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad192 · Cited by 16
“When a new variant emerges, it is crucial for policy and decision-making to characterize novel mutations (15, 13, 14), estimate the growth advantage of the new variant with respect to the existing ones (16), and quantify the effectiveness of currently available vaccines (17, 18).”
Yeast-based screening platforms to understand and improve human health
Deichmann, M., Hansson, F. G., & Jensen, E. D. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.04.003 · Cited by 13
Schöfbänker, M., Günther, T., Lorentzen, E. U., Romberg, M.-L., Hennies, M. T., Neddermeyer, R., Müller, M. M., Mellmann, A., Bojarzyn, C. R., Lenz, G., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012624 · Cited by 16
“Located in an epitope recognised by most individuals with anamnestic infection and vaccination, they confer partial resistance to convalescent sera and broad resistance to bamlanivimab and other class 2 neutral-ising monoclonal antibodies [48,52,53,55–57].”
BackgroundBamlanivimab as monotherapy in two immunocompromised patients with COVID-19
Destras, G., Assaad, S., Bal, A., Bouscambert‐Duchamp, M., Avrillon, V., Simon, B., Valette, M., Blay, J., Lina, B., Frobert, É., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00189-0 · Cited by 15
Wouters, E., Verbrugghe, C., Devloo, R., Debruyne, I., Clippel, D. D., Heddegem, L. V., Asch, K. V., Gaver, V. V., Vanbrabant, M., Muylaert, A., et al. (2021) · Transfusion · doi:10.1111/trf.16652 · Cited by 12
Yue, S., Li, Z., Lin, Y., Yang, Y., Yuan, M., Pan, Z., Li, H., Gao, L., Zhou, J., Tang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751584 · Cited by 14
Zhao, X., Xiong, D., Luo, S., & Duan, L. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp00449f · Cited by 13
Mannsverk, S., Bergholm, J., Palanisamy, N., Ellström, P., Kaden, R., Lindh, J. G., & Lennerstrand, J. (2022) · Virology Journal · doi:10.1186/s12985-022-01896-x · Cited by 27
Conformational stability of SARS-CoV-2 glycoprotein spike variants
Arruda, H. R. S., Lima, T. M., Alvim, R. G. F., Victorio, F. B. A., de Abreu, D. P. B., Marsili, F. F., Cruz, K. D., Marques, M. A., Sosa‐Acosta, P., Quiñones‐Vega, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105696 · Cited by 14
Omicron BA.2 specifically evades broad sarbecovirus neutralizing antibodiesPreprint
Cao, Y., Yisimayi, A., Jian, F., Xiao, T., Song, W., Wang, J., Du, S., Zhang, Z., Liu, P., Hao, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.479349 · Cited by 12
Lennerstrand, J., & Palanisamy, N. (2021) · Viruses · doi:10.3390/v13101974 · Cited by 14
Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain
Patrick, C., Upadhyay, V., Lucas, A., & Mallela, K. M. G. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167622 · Cited by 12
Kwon, H., Košíková, M., Tang, W., Ortega‐Rodriguez, U., Radvák, P., Xiang, R., Mercer, K. E., Muskhelishvili, L., Davis, K., Ward, J. M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105507 · Cited by 11
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults
Raiser, F., Davis, M., Adelglass, J. M., Cai, M. R., Chau, G., Cloney-Clark, S., Eickhoff, M., Kalkeri, R., McKnight, I., Plested, J. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.056 · Cited by 12
Li, Y., & Li, J. Z. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.004 · Cited by 17
Self-citationZaccaria, M., Genovese, L., Dawson, W., Cristiglio, V., Nakajima, T., Johnson, W. E., Farzan, M., & Momeni, B. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac180 · Cited by 12
Nechooshtan, R., Ehrlich, S., Vitikainen, M., Makovitzki, A., Dor, E., Marcus, H., Hefetz, I., Pitel, S., Wiebe, M. G., Huuskonen, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122119 · Cited by 12
Guo, H., Jiang, J., Shen, S., Ge, X., Fan, Q., Zhou, B., Cheng, L., Ju, B., & Zhang, Z. (2023) · iScience · doi:10.1016/j.isci.2023.106283 · Cited by 12
Verstraete, M. M., Heinkel, F., Li, J., Cao, S., Tran, A., Halverson, E. C., Gene, R. W., Stangle, E., Silva‐Moreno, B., Arrafi, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2212415 · Cited by 12
Self-citationEvolutionary safety of lethal mutagenesis driven by antiviral treatment
Lobinska, G., Pilpel, Y., & Nowak, M. A. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002214 · Cited by 13
SARS-CoV-2: Vaccinology and Emerging therapeutics; Challenges and Future Developments
Adesokan, A. M., Obeid, M. A., & Lawal, A. F. (2022) · Therapeutic Delivery · doi:10.4155/tde-2021-0075 · Cited by 12
Rapid surveillance platforms for key SARS-CoV-2 mutations in DenmarkPreprint
Spieß, K., Gunalan, V., Marving, E. L., Nielsen, S. H., Jørgensen, M. G. P., Fomsgaard, A. S., Nielsen, L., Alfaro‐Núñez, A., Karst, S. M., Mortensen, S., et al. (2021) · medRxiv · doi:10.1101/2021.10.25.21265484 · Cited by 12
Acar, D. D., Witkowski, W., Wejda, M., Wei, R., Desmet, T., Schepens, B., Cae, S. D., Sedeyn, K., Eeckhaut, H., Fijałkowska, D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104960 · Cited by 13
An, R., Yang, H., Tang, C., Li, Q., Huang, Q. M., Wang, H., Wang, J., Zhou, Y., Yang, Y. K., Chen, H., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02007-8 · Cited by 12
SARS-CoV-2 epidemiology, kinetics, and evolution: A narrative review
Alizon, S., & Sofonea, M. T. (2025) · Virulence · doi:10.1080/21505594.2025.2480633 · Cited by 16
“They were first used to test affinity to ACE2, and later to evaluate immune escape properties [134].”
Pramanik, A., Mayer, J. A., Sinha, S. S., Sharma, P. C., Patibandla, S., Gao, Y., Corby, L. R., Bates, J. T., Bierdeman, M. A., Tandon, R., et al. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00573 · Cited by 14
SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity
Zhang, Y., Jiang, N., Qi, W., Li, T., Zhang, Y., Wu, J., Zhang, H., Zhou, M., Cui, P., Yu, T., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac106 · Cited by 11
Evaluation of SARS-CoV-2-Specific T-Cell Activation with a Rapid On-Chip IGRA
Ning, B., Chandra, S., Rosen, J., Multala, E., Argrave, M., Pierson, L. M., Trinh, I. V., Simone, B. K., Escarra, M. D., Drury, S. S., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c09018 · Cited by 11
Antibody accessibility determines location of spike surface mutations in SARS-CoV-2 variants
von Bülow, S., Sikora, M., Blanc, F. E. C., Covino, R., & Hummer, G. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010822 · Cited by 10
Schröder, S., Richter, A. M., Veith, T., Emanuel, J., Gudermann, L., Friedmann, K., Jeworowski, L. M., Mühlemann, B., Jones, T. C., Müller, M. A., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02154-4 · Cited by 10
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
Huang, K.-Y. A., Zhou, D., Tan, T. K., Chen, C., Duyvesteyn, H. M. E., Zhao, Y., Ginn, H. M., Qin, L., Rijal, P., Schimanski, L. M., et al. (2021) · Theranostics · doi:10.7150/thno.65563 · Cited by 13
Holistic Resilience Index: measuring the expected country resilience to pandemic
Pileggi, S. F. (2022) · Quality & Quantity · doi:10.1007/s11135-021-01296-3 · Cited by 13
End-point RT-PCR based on a conservation landscape for SARS-COV-2 detection
Cruz‐Rangel, A., Gómez-Romero, L., Cisneros-Villanueva, M., de Anda‐Jáuregui, G., Luna-Pineda, V. M., Cedro‐Tanda, A., Campos‐Romero, A., Mendoza-Vargas, A., Reyes‐Grajeda, J. P., Hidalgo‐Miranda, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07756-6 · Cited by 11
Sims, J. J., Lian, S., Meggersee, R., Kasimsetty, A., & Wilson, J. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271359 · Cited by 10
Ghoula, M., Kongmeneck, A. D., Eid, R., Camproux, A., & Moroy, G. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c01467 · Cited by 12
Recurrent independent emergence and transmission of SARS-CoV-2 Spike amino acid H69/V70 deletionsPreprint
Gupta, R. K., Kemp, S. A., Harvey, W. T., Lytras, S., Carabelli, A. M., & Robertson, D. L. (2021) · Research Square · doi:10.21203/rs.3.rs-136937/v1 · Cited by 12
Goike, J., Hsieh, C., Horton, A. P., Gardner, E. C., Bartzoka, F., Wang, N., Javanmardi, K., Herbert, A. S., Abbasi, S. A., Renberg, R. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.07.438849 · Cited by 13
Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variantPreprint
Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Higuchi, Y., Li, S.-L., Suzuki, T., et al. (2021) · bioRxiv · doi:10.1101/2021.12.22.473804 · Cited by 11
Tu, Y., & Meng, X. (2023) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2023.06.023 · Cited by 10
Alfaleh, M. A., Alsulaiman, R. M., Almahboub, S. A., Nezamuldeen, L., Zawawi, A., Aljehani, N. D., Yasir, M., Abdulal, R. H., Alkhaldi, R. K., Helal, A., et al. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad030 · Cited by 12
Hannon, W. W., & Bloom, J. D. (2024) · The Journal of Open Source Software · doi:10.21105/joss.06129 · Cited by 11
Self-citationChi, L. A., Barnes, J. E., Patel, J. S., & Ytreberg, F. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-72491-z · Cited by 12
“The insights gained here were only possible due to the extensive data generated by DMS in several studies 14,32–37 , emphasizing the crucial role of ongoing data collection and analysis in advancing infectious disease research.”
Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses
Rexhepaj, M., Asarnow, D. E., Perruzza, L., Park, Y., Guarino, B., Mccallum, M., Culap, K., Saliba, C., Leoni, G., Balmelli, A., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.10.001 · Cited by 10
Self-citationOluka, G. K., Sembera, J., Katende, J. S., Ankunda, V., Kato, L., Kurshan, A., Graham, C., Seow, J., Doores, K. J., Malim, M. H., et al. (2025) · Vaccines · doi:10.3390/vaccines13020143 · Cited by 9
Predicting high-fitness viral protein variants with Bayesian active learning and biophysics
Huot, M., Wang, D., Liu, J., & Shakhnovich, E. I. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2503742122 · Cited by 14
Ehling, R. A., Minot, M., Overath, M. D., Sheward, D. J., Han, J., Gao, B., Taft, J. M., Pertseva, M., Weber, C. R., Frei, L., et al. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101391 · Cited by 8
White, I. A., Tamot, N., Doddareddy, R., Ho, J., Jiao, Q., Harvilla, P. B., Yang, T., Geist, B. J., Borrok, M. J., Truppo, M. D., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1987180 · Cited by 11
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2
Saunders, N., Planas, D., Bolland, W., Rodriguez, C., Fourati, S., Buchrieser, J., Planchais, C., Prot, M., Staropoli, I., Guivel‐Benhassine, F., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103934 · Cited by 13
“It will be worth determining whether other antibodies targeting the NTD super antigenic site 39,48 are less active against AY.4.2.”
InfluentialRodrigues‐da‐Silva, R. N., Conte, F. D. P., da Silva, G., Carneiro-Alencar, A. L., Gomes, P. R., Kuriyama, S. N., Neto, A. A. F., & Lima‐Junior, J. D. C. (2023) · Viruses · doi:10.3390/v15040923 · Cited by 13
Human behavior in the time of COVID-19: Learning from big data
Lyu, H., Imtiaz, A., Zhao, Y., & Luo, J. (2023) · Frontiers in Big Data · doi:10.3389/fdata.2023.1099182 · Cited by 11
Luo, Y., Liu, S., Xue, J., Yang, Y., Zhao, J., Sun, Y., Wang, B., Yin, S., Li, J., Xia, Y., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00534-2 · Cited by 10
Self-citationHaploCoV: unsupervised classification and rapid detection of novel emerging variants of SARS-CoV-2
Chiara, M., Horner, D. S., Ferrandi, E., Gissi, C., & Pesole, G. (2023) · Communications Biology · doi:10.1038/s42003-023-04784-4 · Cited by 12
Majoumo‐Mbe, F., Sangbong, N. A., Tcho, A. T., Namba-Nzanguim, C. T., Simoben, C. V., Eni, D. B., Isa, M. A., Poli, A. N. R., Cassel, J. A., Salvino, J. M., et al. (2024) · Chemical Papers · doi:10.1007/s11696-023-03274-5 · Cited by 10
Sierra SARS-CoV-2 sequence and antiviral resistance analysis program
Tzou, P. L., Tao, K., Sahoo, M. K., Pond, S. L. K., Pinsky, B. A., & Shafer, R. W. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105323 · Cited by 11
“mAb resistance mutations were defined as Spike mutations with a median ≥5 fold reduction in susceptibility compared with wildtype according to CoV-RDB and/or having an escape fraction ≥0.1 in the deep mutational scanning (DMS) platform developed by the Bloom Laboratory at the Fred Hutchinson Cancer Research Center [20…”
BackgroundInfluentialEarly detection of emerging SARS-CoV-2 variants of interest for experimental evaluation
Wallace, Z. S., Davis, J. J., Niewiadomska, A. M., Olson, R., Shukla, M. P., Stevens, R. L., Zhang, Y., Zmasek, C. M., & Scheuermann, R. H. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.1020189 · Cited by 8
Logue, J., Johnson, R. M., Patel, N., Zhou, B., Maciejewski, S. M., Zhou, H., Portnoff, A. D., Tian, J.-H., McGrath, M. E., Haupt, R. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.08.447631 · Cited by 10
Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational LearningPreprint
Taft, J. M., Weber, C. R., Gao, B., Ehling, R. A., Han, J., Frei, L., Metcalfe, S. W., Yermanos, A., Kelton, W., & Reddy, S. T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.07.471580 · Cited by 10
Ouyang, J., Zaongo, S. D., Harypursat, V., Li, X., Routy, J., & Chen, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.945448 · Cited by 11
Wang, S., Zou, X., Li, Z., Fu, J., Fan, H., Yu, H., Dèng, F., Huang, H., Peng, J., Zhao, K., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.791600 · Cited by 13
Lanari, M., Venturini, E., Pierantoni, L., Stera, G., Gattinara, G. C., Esposito, S., Favilli, S., Franzonı, E., Fusco, E., Lionetti, P., et al. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-021-01187-1 · Cited by 10
Borghi, M., Gallinaro, A., Pirillo, M. F., Canitano, A., Michelini, Z., Angelis, M. L. D., Cecchetti, S., Tinari, A., Falce, C., Mariotti, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147953 · Cited by 9
Moesslacher, C. S., Kohlmayr, J. M., & Stelzl, U. (2021) · Microbial Cell · doi:10.15698/mic2021.08.756 · Cited by 11
Dong, R., Jiang, L., Yang, T., Wang, C., Zhang, Y., Chen, X., Xie, J., Guo, Y., Weng, L., Kang, Y. M., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02045-21 · Cited by 9
Yoon, J., Nekongo, E. E., Patrick, J. E., Hui, T., Phillips, A. M., Ponomarenko, A. I., Hendel, S. J., Sebastian, R. M., Zhang, Y. M., Butty, V. L., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001569 · Cited by 9
Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies
Chen, J., & Wei, G. (2022) · Communications in Information and Systems · doi:10.4310/cis.2022.v22.n3.a3 · Cited by 9
Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency
Markarian, N. M., Galli, G., Patel, D., Hemmings, M., Nagpal, P., Berghuis, A. M., Abrahamyan, L. G., & Vidal, S. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.933983 · Cited by 10
Jabr, R., Khatri, A. M., Anderson, A. D., Garcia, L. A. C., Viotti, J. B., Natori, Y., Raja, M. A., Camargo, J. F., & Morris, M. I. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14006 · Cited by 8
Pearson, J., Wessler, T., Chen, A., Boucher, R. C., Freeman, R., Lai, S. K., Pickles, R. J., & Forest, M. G. (2023) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2023.111470 · Cited by 9
“[25, 26, 27, 28, 29, 31, 32, 36, 38, 39], [40, 41, 42, 43, 44, 15, 45, 46, 47, 48], [49]), the infection, cellular uptake, replication, and shedding mechanisms altered by these mutations are much harder to identify and quantify [41], with a few notable exceptions:”
Vellas, C., Bello, A. D., Gaube, G., Trémeaux, P., Jeanne, N., Ranger, N., Martin‐Blondel, G., Delobel, P., Kamar, N., & Izopet, J. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac093 · Cited by 10
Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike proteinPreprint
Hsieh, F.-L., & Chang, T.-H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.29.446300 · Cited by 9
Tao, K., Tzou, P. L., Pond, S. L. K., Ioannidis, J. P. A., & Shafer, R. W. (2022) · Preprints.org · doi:10.20944/preprints202203.0155.v1 · Cited by 9
Allman, B. E., Vieira, L., Diaz, D. J., & Wilke, C. O. (2025) · Journal of The Royal Society Interface · doi:10.1098/rsif.2024.0598 · Cited by 11
Passive immune therapies: another tool against COVID-19
Estcourt, L. J. (2021) · Hematology · doi:10.1182/hematology.2021000299 · Cited by 8
Dynamic SARS-CoV-2 emergence algorithm for rationally-designed logical next-generation vaccines
Maison, D. P., Ching, L. L., Cleveland, S. B., Tseng, A. C., Nakano, E. T., Shikuma, C. M., & Nerurkar, V. R. (2022) · Communications Biology · doi:10.1038/s42003-022-04030-3 · Cited by 10
Li, L., Gao, M., Li, J., Xie, X., Zhao, H., Wang, Y., Xu, X., Zu, S., Chen, C., Wan, D., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104401 · Cited by 8
Self-citationPruvost, T., Mathieu, M., DuBois, S. G., Maillère, B., Vigne, E., & Nozach, H. (2023) · mAbs · doi:10.1080/19420862.2023.2175311 · Cited by 10
Kharchenko, E. P. (2021) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2021-20-1-4-19 · Cited by 12
Curreli, F., Ahmed, S., Victor, S. M. B., Drelich, A. K., Panda, S. S., Altieri, A., Kurkin, A. V., Tseng, C.-T. K., Hillyer, C. D., & Debnath, A. K. (2021) · Viruses · doi:10.3390/v14010069 · Cited by 9
Kuramochi, T., Gan, S. W., Ho, A. W. S., Wang, B., Kageji, N., Nambu, T., Iida, S., Okuda-Miura, M., Chia, W. S., Yeo, C. Y., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2040350 · Cited by 7
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants
Li, L., Gao, M., Jiao, P., Zu, S., Deng, Y., Wan, D., Cao, Y., Duan, J., Aliyari, S. R., Li, J., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00794-7 · Cited by 8
Self-citationWang, B., & Gamazon, E. R. (2022) · iScience · doi:10.1016/j.isci.2022.104500 · Cited by 8
Agarwal, D. K., Hunt, A. C., Shekhawat, G. S., Carter, L. P., Chan, S., Wu, K., Cao, L., Baker, D. A., Lorenzo-Redondo, R., Ozer, E. A., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01221 · Cited by 10
Prediction of antibody binding to SARS-CoV-2 RBDs
Wang, E. J. D. (2022) · Bioinformatics Advances · doi:10.1093/bioadv/vbac103 · Cited by 11
Reingruber, J., Papale, A., Ruckly, S., Timsit, J., & Holcman, D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278882 · Cited by 8
Outsmarting Pathogens with Antibody Engineering
Qerqez, A. N., Silva, R. P., & Maynard, J. A. (2023) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101121-084508 · Cited by 9
Genotype–phenotype landscapes for immune–pathogen coevolution
Moulana, A., Dupic, T., Phillips, A. M., & Desai, M. M. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.03.006 · Cited by 11
“Later DMS studies have identi fi ed other key spike protein sites in which mutations are likely to lead to immune escape variants [85,98].”
BackgroundPostvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study
Mathema, B., Chen, L., Chow, K. F., Zhao, Y., Zody, M. C., Mediavilla, J. R., Cunningham, M. H., Composto, K., Lee, A., Oschwald, D. M., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01882-21 · Cited by 7
The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced ImmunityPreprint
Shang, E., & Axelsen, P. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.13.422567 · Cited by 9
Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.22.441007 · Cited by 8
Rochman, N. D., Faure, G., Wolf, Y. I., Freddolino, P. L., Zhang, F., & Koonin, E. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.30.458225 · Cited by 8
“The WT/Delta RBD-ACE2 footprint consists of 37 sites whereas the WT/Delta RBD-NAb footprint includes 51 sites (Table 1).”
Tzou, P. L., Tao, K., Pond, S. L. K., & Shafer, R. W. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.24.469823 · Cited by 8
Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal modelsPreprint
Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J., Fan, C.-H., Schulz, J. E., Gnanapragasam, P. N. P., et al. (2022) · bioRxiv · doi:10.1101/2022.03.25.485875 · Cited by 5
Self-citationRuiz, F., Foreman, W. B., Lilly, M., Baharani, V. A., Depierreux, D. M., Chohan, V., Taylor, A. L., Guenthoer, J., Ralph, D., Matsen IV, F. A., et al. (2024) · PLOS Pathogens · doi:10.1371/journal.ppat.1012650 · Cited by 7
Self-citationAlshahrani, M., Parikh, V., Foley, B., & Verkhivker, G. M. (2025) · Viruses · doi:10.3390/v17060741 · Cited by 8
“This is consistent with reported data that any substitution of the helix breaker P337 resulted in a complete S309 escape [106].”
Metadata
- Authors
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D.
- Affiliations
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Science
- Published
- 2021-02-19
- Volume
- 371
- Issue
- 6531
- Pages
- 850-854
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963219
- OpenAlex
- W3125266951
- Cited by
- 743
- References
- 40
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 56 · 2023: 104 · 2022: 232 · 2021: 279
- FWCI
- 53.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute (Investigator)
- National Institute of Allergy and Infectious Diseases (R01AI127893, R01AI141707)
- Bill and Melinda Gates Foundation (INV-004949)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Massachusetts Consortium for Pathogen Readiness
- Washington Research Foundation (Innovation Fellow)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody escape, receptor binding domain, viral mutations, monoclonal antibodies, antibody binding, viral surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.